Finance

Lists
Why is VTVT down 2,31%?
Dive Deeper
VTVT:NASDAQ
vTv Therapeutics Inc
30,46 US$
-2,31%
(-0,72) 1D
12 ოქტ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VTVT...
Open
31,12 US$
High
31,18 US$
Low
30,28 US$
Mkt. cap
120,44 მლნ.
Avg. vol.
40,34 ათ.
Volume
0,00
52-wk high
44,00 US$
52-wk low
19,80 US$
EPS
-1,06 US$
Beta
0,23
Shares outstanding
3,95 მლნ.
No. of employees
26
Open
31,12 US$
High
31,18 US$
Low
30,28 US$
Mkt. cap
120,44 მლნ.
Avg. vol.
40,34 ათ.
Volume
0,00
52-wk high
44,00 US$
52-wk low
19,80 US$
EPS
-1,06 US$
Beta
0,23
Shares outstanding
3,95 მლნ.
No. of employees
26
News stories
From web sources and news partners
About vTv Therapeutics Inc
CEO-
Employees26
Founded2015
Headquartersჰაი-პოინტი, ჩრდილოეთი კაროლინა, ამერიკის შეერთებული შტატები
Sector-
Websitevtvtherapeutics.com
Analyst ratings
Based on 5 analysts giving stock ratings to VTVT in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for VTVT in the last 3 months.
Highest
Current 30,46 US$
67,00 US$ (+119,96%)
Average
56,80 US$ (+86,47%)
Lowest
42,00 US$ (+37,89%)
Analyst
Recommendation
Action
Price target
Projected
Date
Adam Walsh
Roth MKM
Buy
Reiterated
58,00 US$
+90,4%
10/06/2026
Patrick Dolezal
LifeSci Capital
Buy
Maintained
60,00 US$
+97%
10/05/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
42,00 US$
+37,9%
09/21/2026
Kambiz Yazdi
BTIG
Buy
Maintained
57,00 US$
+87,1%
08/06/2026
Ritu Baral
TD Cowen
Buy
Maintained
67,00 US$
+120%
08/07/2026
Michael King
Rodman & Renshaw
Buy
Initiated
67,00 US$
+120%
06/30/2026
James Molloy
Alliance Global Partners
Buy
Reiterated
55,00 US$
+80,6%
05/14/2026
Michael DiFiore
Evercore ISI
Buy
Initiated
44,00 US$
+44,5%
03/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
36,84 მლნ.
-
Cost of goods sold
7,02 მლნ.
3,91 მლნ.
8,98 მლნ.
8,77 მლნ.
Cost of revenue
7,02 მლნ.
3,91 მლნ.
8,98 მლნ.
8,77 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,68 მლნ.
3,98 მლნ.
4,60 მლნ.
5,16 მლნ.
Operating expense
3,68 მლნ.
3,98 მლნ.
4,60 მლნ.
5,16 მლნ.
Total operating expenses
10,70 მლნ.
7,88 მლნ.
13,58 მლნ.
13,93 მლნ.
Operating income
-10,70 მლნ.
-7,88 მლნ.
23,26 მლნ.
-13,93 მლნ.
Other non operating income
-40,00 ათ.
-117,00 ათ.
33,00 ათ.
64,00 ათ.
EBT including unusual items
-10,34 მლნ.
-7,14 მლნ.
24,13 მლნ.
-13,05 მლნ.
EBT excluding unusual items
-10,34 მლნ.
-7,14 მლნ.
24,13 მლნ.
-13,05 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-8,70 მლნ.
-7,14 მლნ.
24,13 მლნ.
-13,05 მლნ.
Net profit margin
-
-
65,51%
-
Earnings per share
-1,08
-0,58
1,65
-1,05
Interest and investment income
399,00 ათ.
865,00 ათ.
838,00 ათ.
812,00 ათ.
Interest expense
-5,00 ათ.
-1,00 ათ.
-
-
Net interest expenses
394,00 ათ.
864,00 ათ.
838,00 ათ.
812,00 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-10,70 მლნ.
-7,88 მლნ.
23,26 მლნ.
-13,93 მლნ.
Gain or loss from assets sale
-
6,00 ათ.
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები